The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
A new research report by SNS Insider projects a significant expansion for the global Hormone Replacement Therapy (HRT) market over the next decade. The market, valued at $20.36 billion in 2025, is expected to exceed $34.16 billion by 2035, representing a steady compound annual growth rate (CAGR) of approximately 5.3%. Analysts attribute this upward trend to the rising prevalence of hormonal imbalances and the healthcare needs of an aging global population. Major pharmaceutical players, including Pfizer (PFE), AbbVie (ABBV), and Novo Nordisk (NVO), are well-positioned to capitalize on this sector's long-term growth. The forecast also highlights potential upside for healthcare-focused instruments like the XLV ETF as treatment accessibility improves. Overall, the data suggests a robust outlook for specialized biopharmaceutical providers through 2035.
Sign up free to access this content
Create Free Account